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NOFSA statement on generic 
bisphosphonates
To the Editor: Dr Nic de Jongh,1 Medical Director of Cipla Med-
pro, expressing the wish to ‘… set the record straight in terms of 
inaccurate and irrelevant comments [by] the National Osteopo-
rosis Foundation of South Africa’,1 addresses two separate but 
interrelated topics: the pharmacology of alendronate, and the 
fundamental issue of who is ultimately responsible for patient 
care and maintaining health delivery standards in this country.
The debate on generic bisphosphonates has become rhetori-
cal, and I therefore limit my comments to the specific points 
raised by Dr De Jongh.  
1. Our reference to the ‘Notice of rejection’ did not involve an 
old application of 1998/9, but was published in the Government 
Gazette in 2004.2  
2. We remain concerned about the paucity of scientific 
literature on the pharmacology of generic bisphosphonates.  
The three articles quoted by Dr De Jongh, all originating 
directly from the pharmaceutical industry and published in 
the journal Arzneimittelforschung, often involved small subject 
numbers (only 23 in one study) and with other limitations 
are unlikely to contribute significantly to the scientific depth 
of our understanding of the subject. Moreover, none of these 
articles involved the local generic alendronate Osteobon, so if 
Dr De Jongh is consistent they should probably be regarded as 
irrelevant.  
3. The suggestion that NOFSA is questioning the integrity 
and credibility of the Medicines Control Council is absurd. 
Given the lack of data on generic bisphosphonates and the 
rather unique pharmacokinetic profile of alendronate (e.g. 
extremely poor intestinal absorption of < 1%; high inter- and 
intra-individual variability), it is surely understandable that 
responsible care providers would have concerns about safety 
and efficacy – it is also not surprising that the drug was placed 
on the MCC’s Non-Substitutable List. The precedent of the 
MCC approving a generic drug, yet placing the ethical drug 
on their Non-Substitutable list, is well established, not unique 
to alendronate, and no reason whatsoever to accuse NOFSA of 
questioning the integrity of the MCC. 
4. The mechanism of bisphosphonate-induced oesophageal 
irritation may include inhibition of the cholesterol biosyn-
thetic pathway, since this appears to be the primary molecular 
mechanism of action of these drugs. However, those of us who 
daily treat osteoporosis with bisphosphonates know that the 
dominant, if not the only, effect is a direct, presystemic toxic one 
on the gut – hence the ability to limit oesophageal irritation by 
not lying down after oral ingestion of the drug, and prevention 
of this side-effect by giving the drug intravenously.
Who is responsible for patient care and maintaining health 
delivery standards as these pertain to osteoporosis in general, 
and the pharmacotherapy of the disease in particular?  Accord-
ing to De Jongh and Cipla Medpro, neither local clinicians nor 
international world experts on osteoporosis are ‘… appropriate 
experts on regulatory science’.  Even clinical pharmacologists 
are not suitably equipped!  Whereas I acknowledge the fact 
that there is no room for an arrogant, medical profession that 
unilaterally dictates what the treatment of osteoporosis should 
comprise, it would clearly not be in our patients’ best interests 
if this role were to be taken over by the pharmaceutical industry 
or by anyone else.
It is NOFSA’s right and a core responsibility to remain 
abreast of every aspect of osteoporosis management.  Therefore 
to suggest that ‘… NOFSA should rather focus on the goals of 
its own organisation and acknowledge the benefits of generic 
alendronate …’ is undeserving of further comment.  NOFSA 
will continue to assess all new developments, including new 
pharmaceutical agents in the field of metabolic bone disease, 
in a critical, scientific and fair fashion, always insist on sound 
evidence-based data, promote true cost-efficacy, and above all 
else always act in the best interests of the patient.
Stephen Hough
Chairman,  NOFSA
PO Box 481
Bellville, 7535
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Phyto-oestrogens in soy-based 
products – concerns regarding the 
adverse effects on puberty
To the Editor: A large body of evidence documents the role of 
phyto-oestrogens in influencing hormone-dependent states. 
Infants fed soy formula receive high levels of phyto-oestrogens, 
in the form of soy isoflavones, during a stage of development 
at which permanent effects are theoretically possible. Delayed 
effects of soy-based infant formula on subsequent child or 
adult health have thereby been postulated, generating substan-
tial controversy in the lay and medical press.1 Furthermore, 
concerns about possible adverse effects of exposure of infants 
to phyto-oestrogens in soy-based formulas are founded on hy-
pothetical possibilities and are related to knowledge of the role 
of oestrogens at critical stages of development and in mediating 
reproductive or neuro-endocrine disruption in various animal 
species.2
The effects on human pubertal and reproductive develop-
ment of phyto-oestrogen exposure in infancy have not been 
systematically investigated. Therefore, given the lack of data on 
the long-term effects of soy formulas, Strom et al.1 undertook 
a retrospective study among adults who as infants were fed 
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on either soy formula or cow’s milk formula. The researchers 
concluded that exposure to soy formula does not appear to lead 
to different health or reproductive outcomes.
Timing of exposure is also a critical factor in predicting 
potential steroid hormone effects. The devastating effects of di-
ethylstilbestrol taken in early pregnancy only became apparent 
in offspring, who were predisposed to reproductive dysfunc-
tion and adenocarcinoma later in life. This genetic imprinting 
and the effects of phyto-oestrogens on sexual differentiation in 
many mammalian and avian species relate to prenatal rather 
than postnatal exposure. Unfortunately, there appears to be 
no ideal animal model for the human neonate; therefore, it 
is difficult to extrapolate these animal data to infants. Soy-
based formulas are consumed postnatally, not prenatally. Any 
negative effects from phyto-oestrogens might be expected to 
be enhanced by exposure of the fetus to isoflavones from soy 
products consumed during pregnancy.2 
In the absence of practical examples to support adverse ef-
fects of soy-based infant formulas, despite their use for more 
than 30 years, it could be argued that long-term benefits may 
ensue from infant exposure to soy-based formulas contain-
ing isoflavones because this could confer protection later in 
life against hormone-dependent diseases. In this regard, it 
is speculated that the low incidence of hormone-dependent 
diseases in China and Japan, where soy is a staple, may in part 
be a consequence of a lifetime exposure to phyto-oestrogens 
from the traditional diet. The concept of early-life diet influenc-
ing later disease outcome is gaining credence. Interestingly, the 
incidence of such diseases is increasing and this trend appears 
to be related to a move toward a more westernised diet in these 
countries.2
Dhamend Lutchman
Medical Department 
Abbot South Africa
PO Box 7208
Weltevredenpark
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Genetic testing for spinal muscular 
atrophy
To the Editor: We read with interest the description relating 
to spinal muscular atrophy (SMA) in the black South African 
population.1 The authors have described an interesting local 
group. We are, however, concerned that this may not be 
representative of the whole of South Africa. 
We would be particularly interested to hear more about the 
clinical phenotype and epidemiology of this cohort of patients. 
The authors have, for example, included phenotypic patients 
with facial weakness in their grouping. This is of significance 
because the international guidelines (ENMC, 1998) regard 
these as exclusion criteria for SMA.2  In our cohort of patients, 
facial weakness in the SMA molecularly genetically confirmed 
group is not a feature. Our 4 patients who presented with facial 
weakness, and were found to be negative for the common SMN 
(survival motor neuron) gene mutation, were subsequently 
confirmed to have other pathologies (congenital myopathy or 
congenital dystrophy). 
We are concerned that the authors’ findings are not 
representative of the whole of South Africa and that incorrect 
genetic advice could therefore be given to families and patients 
of indigenous African descent. As described in our paper,3 
we found no deviation from the international detection rate 
for the common SMN gene deletion (95 - 100%), regardless of 
our patients’ ancestry. This paper was published in 2002. Our 
figures have not altered since then and have now increased to a 
total of 50 patients assessed clinically and genetically confirmed 
to have SMA, with 22 being of indigenous African origin. We 
have had no patients of indigenous African origin referred 
through the services who complied with the international 
guidelines for SMA and were negative for the common SMN 
gene deletion on genetic testing.  
This discrepancy in SMA findings between two geographi-
cally distinct institutions is of diagnostic import, and we look 
forward to the published evidence from the authors that their 
discordant black patients have some other defect, either local-
ised to the SMN gene or impacting on SMN gene expression.
Jo M Wilmshurst
Felicity Leisang
Howard Hendersen  
Departments of Paediatric Neurology and 
Chemical Pathology 
Red Cross War Memorial Children’s Hospital and 
University of Cape Town 
wilmshur@ich.uct.ac.za
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Can (or should) doctors be 
entrepreneurs?
To the Editor: Traditionally, being entrepreneurial is associated 
with successful business outcomes, and far removed from 
conservative medical practice.
The concept encourages enterprise, initiative and forward 
thinking – definitely not foreign to medical practice.
Modern business schools use newer terms of risk 
management, networking and personal challenge to move 
forward. These principles are critical to surviving changes in 
the practice of medicine wherever one works, as specialist or 
generalist, but one must not move too far from core expertise 
and experience.
One response to change that I have embarked on is the 
challenge of short-term overseas locum work, which has 
several significant benefits. Firstly, it is immensely satisfying 
professionally to function and cope in a foreign environment. 
Secondly, the financial rewards are definitely worth the effort. 
Thirdly, the break from routine and the opportunity to explore 
a new country is therapeutic, and lastly the logistics can be 
streamlined to minimise disruption to one’s practice.
Business people are praised for international travel 
and promoting foreign trade. South African doctors have 
been negatively influenced by past medical emigration 
and are naturally concerned that an overseas venture will 
be perceived (by colleagues and patients) as the first step 
towards emigration. These fears must be countered by 
openly capitalising on the reality that medical mobility is 
an international phenomenon driven by a world shortage 
of experienced doctors. Gaining overseas experience and 
earning foreign exchange from short-term locums are laudable 
activities; in addition one has the opportunity to reflect on 
medical facilities at home.
My experiences have been gained from general practice 
in Ireland, a beautiful and hospitable country. Currently it is 
possible for South African medical graduates to gain lifelong 
full registration without any need for examinations. This 
status is now under threat and this door of opportunity, like 
many others over the past three decades, is likely to close soon 
as the Irish Medical Council, in its perceived wisdom, has 
recommended that this privilege be rescinded.
Your last chance to register is now.
Be entrepreneurial, you will have no regrets.
Les Smith
95 Forest Drive 
Pinelands
7405
smithprac@absamail.co.za
2010, HIV and international public 
health issues
To the Editor: South Africa’s capacity to hold a successful 
World Cup event in 2010 has been widely discussed. However, 
I have not seen anything on the public health issues of our 
hosting such an event, although these issues seem to be 
considerable.
Images and reports of the World Cup in Germany lead one to 
expect that very large crowds will attend.  They also lead one to 
expect that there will be extensive celebrations in the streets and 
stadiums.  Large sections of the crowd will be foreign tourists, 
exposed to cultures very different from their own. They will 
have all the disadvantages of displaced persons.  These include 
a reduced resistance to engaging in behaviour patterns they 
would regard as unacceptable in their own milieu.
The combination of a large number of displaced persons 
partying and celebrating with free use of alcohol in a country 
with (at present) weak policing makes one expect that our 
emergency services will be stretched to their utmost coping 
with immediate consequences, such as violence, rape and 
alcohol- and drug-related emergencies.
But there is another issue which must be thought through.  
The injection of huge numbers of HIV-naïve partying 
people into a nation with one of the highest incidences of 
HIV infection, and definitely the highest incidence of rape, 
in the world can be expected to result in large numbers of 
newly infected people returning to nations with very low 
HIV prevalences.  That is especially true if they make use of 
local prostitutes.  If the press is to be believed, prostitutes in 
Germany and neighbouring countries did a very brisk trade in 
Germany during the last World Cup. It seems to me that this 
latter danger is so great that it should make us pause in our 
enthusiasm about hosting the 2010 event.  Perhaps, for the sake 
of international public health we should suggest that another 
nation take on the task.  What a dreadful thought!
If these considerations are not enough to make us suggest 
that another nation provide the venue, at least they require that 
we mount an enormous campaign to protect soccer tourists 
with a lot more than a condom message! Education campaigns 
aimed at preventing new HIV infections in our country have 
been singularly unsuccessful. That fact should perhaps make us 
limit our options even further.  Perhaps the event should go to a 
country with a low incidence of HIV and rape!
J V Larsen 
Private Bag X010
Howick 
3290
jonvl@netactive.co.za
        
